资讯
Merck is in a tight spot, balancing blockbuster Keytruda’s looming 2028 patent cliff and rough seas in China’s market.
Merck & Co – known as MSD outside the US and Canada – has shared promising results from a late-stage study of its anti-PD-1 ...
Merck’s Keytruda, with more than 40 approved indications, hasn’t yet been able to crack specifically into ovarian cancer. | ...
Merck offers a 4.2% dividend yield but faces uncertainty with KEYTRUDA's LOE. Click here to find out why MRK stock is a Hold.
Merck is expanding in oncology, immunology, and vaccines through acquisitions and R&D. Find out what makes MRK a stable GARP ...
US drugmaker Merck &Co will present data on the use of its PD-1 inhibitor Keytruda in four new cancer types later this week as it jostles for territory in the fast-growing immuno-oncology sector.
Leerink Partners previews the drugs likely to be subject to the Inflation Reduction Act’s next price negotiations as the ...
Merck (NYSE:MRK) announced Thursday that its bestselling therapy, Keytruda, as part of a combination regimen, reached the ...
Merck's Phase 3 trial of Keytruda plus chemo met progression-free survival and overall survival goals in platinum-resistant ...
Merck & Co’s attempts to move its checkpoint inhibitor Keytruda into prostate cancer have been blocked once again, continuing a run of disappointing studies with immunotherapies in the disease.
Merck & Co. ‘s planned debut this fall of an injectable form of its breakthrough cancer treatment Keytruda will simplify care, expand access, and save more lives, the company says. But by shifting ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果